The government hopes to limit cases in which NICE determines a treatment isn't cost effective after the MHRA has deemed it ...

A Diaceutics report looks at when in the diagnosis, testing, and treatment process NSCLC patients lose out on access to precision medicine.

Early clinical data indicates the treatment leads to dose-dependent increases in functional AAT protein, which is altered in the condition.

BriGene Biosciences supported Grit with technology transfer, manufacturing, and regulatory requirements for the IND for GT307.

In the third phase, the Diagnostics Accelerator will support the development of multi-marker panels leveraging digital and AI tools that can accelerate precision treatments.

The firm originally submitted the application seeking approval for TLX101-Px in August 2024, but the agency requested additional efficacy analysis.

Sarepta plans to evaluate the gene therapy with a new immunosuppressive regimen in the hopes of relaunching it in the non-ambulatory indication.

The next question researchers want to answer is whether urine-derived lymphocytes can actually help inform responses to ...

The agency previously declined to approve Ebvallo for Epstein-Barr virus-positive post-transplant lymphoproliferative disease and requested a new trial.

Waiv, previously operating as Owkin Dx, will expand global access to a pipeline of AI-driven digital pathology and multimodal tests for cancer.

The firm said it expects to file an investigational new drug application for the autologous CAR T-cell therapy TPST-2003 in the US by the end of the year.